EVGN vs. NLTX, BIOR, SLS, ACST, EFTR, SNCE, POCI, APM, CODX, and LIAN
Should you be buying Evogene stock or one of its competitors? The main competitors of Evogene include Neoleukin Therapeutics (NLTX), Biora Therapeutics (BIOR), SELLAS Life Sciences Group (SLS), Acasti Pharma (ACST), eFFECTOR Therapeutics (EFTR), Science 37 (SNCE), Precision Optics (POCI), Aptorum Group (APM), Co-Diagnostics (CODX), and LianBio (LIAN). These companies are all part of the "medical" sector.
Evogene (NASDAQ:EVGN) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, community ranking, analyst recommendations, valuation and media sentiment.
Evogene received 169 more outperform votes than Neoleukin Therapeutics when rated by MarketBeat users. Likewise, 60.33% of users gave Evogene an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.
In the previous week, Evogene had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 3 mentions for Evogene and 0 mentions for Neoleukin Therapeutics. Evogene's average media sentiment score of 0.96 beat Neoleukin Therapeutics' score of 0.00 indicating that Evogene is being referred to more favorably in the media.
Evogene presently has a consensus price target of $3.62, suggesting a potential upside of 388.67%. Neoleukin Therapeutics has a consensus price target of $30.00, suggesting a potential downside of 41.06%. Given Evogene's higher probable upside, equities analysts clearly believe Evogene is more favorable than Neoleukin Therapeutics.
Evogene has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.
10.4% of Evogene shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 7.4% of Evogene shares are owned by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Neoleukin Therapeutics has a net margin of 0.00% compared to Evogene's net margin of -423.39%. Neoleukin Therapeutics' return on equity of -37.22% beat Evogene's return on equity.
Evogene has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.
Summary
Evogene beats Neoleukin Therapeutics on 12 of the 16 factors compared between the two stocks.
Get Evogene News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools